New guidelines for treatment of patients with atrial fibrillation

Robert Čihák

Interv Akut Kardiol. 2007;6(5):167-168  

Catheter ablation of ventricular fibrillation by elimination of trigger premature ventricular contractions

Hanka Mlčochová, Petr Peichl, Jan Bytešník, Josef Kautzner

Interv Akut Kardiol. 2007;6(5):173-176  

Sudden cardiac death (SCD) is mainly caused by ventricular fibrillation (VF) or rapid ventricular tachycardia. Implantation of cardioverter-defibrilator (ICD) has been adopted as the effective method for primary or secondary prevention of SCD. However, many patients suffer from frequent ICD discharges and the effect of antiarrhythmic drugs is limited. Other patients may encounter arrhythmic storm. Recent studies have shown that VF can be initiated by premature ventricular contractions originating mostly in the distal Purkinje fibers or right ventricular outflow tract. Catheter ablation of these focal triggers could suppress or even eliminate recurrences...

Role of selective factor Xa inhibition in antithrombotic treatment

Ota Hlinomaz

Interv Akut Kardiol. 2007;6(5):178-180  

Factor Xa has an important role in the coagulation cascade. Selective factor-Xa inhibitors inhibit thrombin generation and thrombus formation. Rivaroxaban, otamixaban and apixaban are direct, selective factor Xa inhibitors. Fondaparinux and idraparinux selectively bind antithrombin and cause indirect inhibition of factor Xa. Fondaparinux was recently established as a leading antithrombotic drug in the treatment of acute coronary syndromes without ST segment elevation.

Indications of cardiothoracic surgery of the most frequent valve disease from perspective of new guidelines

Pavel Marcián, Petr Němec

Interv Akut Kardiol. 2007;6(5):182-187  

The aim of the article is a review of indications for cardiothoracic surgery of the most frequent valve disease in adults according latest guidelines valid in the Czech Republic, Europe and also in the USA as published last and this year.

Cardiogenic shock due to prosthetic aortic valve obstruction

Interv Akut Kardiol. 2007;6(5):188-191  

Prosthetic valve dysfunction is a relatively rare but potentially fatal complication. The authors describe the case of sixty years old woman with cardiogenic shock due to prosthetic aortic valve obstruction. Principal causes of these dysfunctions and the possibilities of diagnostics and management are discussed.

Purulent pericarditis with cardiac tamponade

David Vindiš, Pavel Třeštík, Petr Němec, Hana Študentová

Interv Akut Kardiol. 2007;6(5):192-194  

Purulent pericarditis is a rare disease, often remarked as a complication of an infection originating elswhere in the body. The course of the disease is typically fulminant (often with evolving of cardiac tamponade), with high mortality rate (100 % in untreated patients, around 40 % in treated patients). Early diagnosing of this condition is important. The treatment is based on targeted antibiotic therapy and pericardiocentesis. If this approach is ineffective, surgical pericardial fenestration with drainage is needed. The case report describes purulent pericarditis in a 73-year-old man with onset of cardiac tamponade in the course of...

An unusual case of thrombosis after the replacement of the aortic valve with a bioprosthesis

Jana Matoušková, Petr Niederle, Miroslava Benešová, Iva Zemanová, Miloš Táborský

Interv Akut Kardiol. 2007;6(5):195-199  

This is the case of a 69 year old woman who died of heart failure as a result of the rapid progression of thrombotic obstruction of the aortic bioprosthesis less than two months after surgery. We discuss the problems with the use of bioprostheses, particularly whether anti-coagulation should be administered during the post-operative period and the therapeutic options in the event of thrombosis. Generally, in low-risk patients (i.e. those with no prior history of thromboembolism, hypercoagulation, atrial fibrillation, findings of thrombi in the heart chambers, left atrium > 55 mm or dysfunction of the left ventricle with EF < 30 %) aortic bioprostheses...

XVIIth Workshop of Interventional Cardiology, April 26-27 2007 Hradec Králové

-

Interv Akut Kardiol. 2007;6(5):205-209  

TRITON-TIMI 38: to dissolve the patient - are we approaching to the goal?

Ivo Varvařovský

Interv Akut Kardiol. 2007;6(5):203-204  

More and more aggressive antiplatelet treatment can decrease the prevalence of ischemic complications of atherosclerosis however at the cost of an increase of serious bleeding complications. Study TRITON-TIMI 38 confiremd the reality for prasugrel, but in he same time it showed an exceptioal efficacy of hte medications in decreasing of stent thrombosis. The selection of patient groups with increased risk of bleeding is the greatest contribution of the study and enables much more effective use of the medication in every day clinical practice.

Easy left internal mammary artery cathetrization and intervention from the left radial approach

Ivo Bernat, Jan Pešek, Jiří Koza, Richard Rokyta

Interv Akut Kardiol. 2007;6(5):200-201